- Nintedanib +12016 | First Faculty of Medicine
- Nintedanib in the treatment of idiopathic pulmonary fibrosis2016 | First Faculty of Medicine
- Nintedanib - interesting alternative forsecond line pulmonaty adenocarcinoma patients2016 | Faculty of Medicine in Pilsen
- Nintedanib, a new angiokinase inhibitor in the treatment of non-small cell lung cancer2013 | Faculty of Medicine in Hradec Králové
- Nintedanib in the treatment of interstitial lung disease - the view of a rheumatologist. Nintedanib in the treatment of interstitial lung disease - the view of a rheumatologist2020 | First Faculty of Medicine
- Tolerability of nintedanib treatment with established immunosuppressive therapy2022 | First Faculty of Medicine, Second Faculty of Medicine
- Targeted treatment of NSCLC with kinase inhibitors - afatinib and nintedanib in clinical pracitce2017 | Faculty of Medicine in Pilsen
- Lung damage in systemic sclerosis, new indication of antifibrotic treatment with nintedanib2020 | Faculty of Medicine in Hradec Králové
- Nintedanib in treating interstitial lung disease associated with systemic scleroderma2021 | First Faculty of Medicine, Second Faculty of Medicine
- Nintedanib v klinické praxi2021 | First Faculty of Medicine, Second Faculty of Medicine
- Komentář k metaanalýze studií nintedanib + docetaxel2018 | Second Faculty of Medicine
- Nintedanib v léčbě idiopatické plicní fibrózy2015 | First Faculty of Medicine
- Role of pirfenidon in idiopathic pulmonary fibrosis treatment2018 | First Faculty of Medicine
- Pharmacotherapy of idiopathic pulmonary fibrosis - current treatment and future concepts2019 | First Faculty of Medicine
- Position of pharmacotherapy in the treatment of idiopathic pulmonary fibrosis2018 | First Faculty of Medicine
- Současné možnosti léčby idiopatické plicní fibrózy - výhledy2020 | Second Faculty of Medicine
- Aggressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment: a case report2020 | Faculty of Medicine in Pilsen
- Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease2019 | First Faculty of Medicine
- Current pharmacotherapy of idiopathic pulmonary fibrosis2016 | First Faculty of Medicine
- Antiangiogenic therapy of lung cancer2018 | Second Faculty of Medicine
- Komentář ke studii (Bezpečnost a snášenlivost nintedanibu u pacientů s idiopatickou plicní fibrózou v USA)2018 | First Faculty of Medicine
- Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer2020 | First Faculty of Medicine
- The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Idiopathic pulmonary fibrosis - from therapeutic nihilism to effective pharmacotherapy2016 | First Faculty of Medicine
- Komentář ke studii (Nintedanib v léčbě idiopatické plicní fibrózy - analýza výsledků studií II. a III. fáze)2016 | First Faculty of Medicine
- This should not happen to respiratory specialist - unfortunate end of IPF story in Czech Republic2015 | First Faculty of Medicine
- Interstitial lung disease, no more stagnant water2015 | First Faculty of Medicine
- Léčba idiopatické plicní fibrózy u pacientů starších osmdesáti let2017 | First Faculty of Medicine
- DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Second Faculty of Medicine